Multiple sclerosis

Disease-a-Month

Volumn 42, Issue 1, 1996, Pages 6-55

  Lynch, Sharon G ^a   Rose, John W ^b,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AZATHIOPRINE; BACLOFEN; BETA1 INTERFERON; CARBAMAZEPINE; CLADRIBINE; CLONIDINE; CORTICOTROPIN; CYCLOPHOSPHAMIDE; DIAZEPAM; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; PHENYTOIN; PREDNISONE; QUININE SULFATE; VALPROIC ACID;

AUTOIMMUNITY; CHRONIC PAIN; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PALLIATIVE THERAPY; PATHOGENESIS; REVIEW; SPASTICITY; TOPICAL DRUG ADMINISTRATION; TREATMENT PLANNING; ADOLESCENT; ADULT; ANIMAL; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE;

ADOLESCENT; ADULT; ANIMALS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DISEASE MODELS, ANIMAL; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS; RECURRENCE;

EID: 84954085248     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-5029(96)90012-7     Document Type: Review

References (147)

1. Multiple sclerosis
2. Multiple sclerosis
3. Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features
4. Neuroimaging in multiple sclerosis
5. Acute VIth cranial nerve dysfunction in multiple sclerosis
6. Correlations of nuclear magnetic resonance imaging, computerized tomography, and clinical profiles in multiple sclerosis
7. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials
8. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden
9. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: Part 2. MRI analysis results of a multicenter, randomized, doubleblind, placebo-controlled trial
10. The epidemiology of multiple sclerosis: principles, achievements, and recommendations
11. Epidemiology of multiple sclerosis.
12. Genetic epidemiology of multiple sclerosis: a survey
13. Genetics of multiple sclerosis
14. A population-based study of multiple sclerosis in twins: update
15. Genetic analysis of autoimmune type I diabetes mellitus in mice
16. Demyelinating diseases
17. Oligodendrocytes in the early course of multiple sclerosis
18. Pathology of multiple sclerosis
19. Tumor necrosis factor identified in multiple sclerosis brain
20. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis
21. Multiple sclerosis: oligodendroglia survival and proliferation in an active established lesion
22. Neurological autoimmune disease and the trimolecular complex of T-lymphocytes
23. Isolation of myelin basic protein-reactive T-cell lines from normal human blood
24. Assessment of antigenic determinants for the human T cell response against myelin basic protein using overlapping synthetic peptides
25. Heterogeneity of the T-cell receptor beta gene rearrangements generated in myelin basic protein-specific T-cell clones isolated from a patient with multiple sclerosis
26. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis
27. T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis
28. Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls
29. Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid
30. Multiple sclerosis is associated with genes within or close to the HLA-DR-DQ subregion on a normal DR15, DQ6, Dug haplotype
31. Genetic susceptibility models in multiple sclerosis
32. Linkage strategies for genetically complex traits. Part 1. Multilocus models
33. Multiple sclerosis: diagnostic usefulness of cerebrospinal fluid
34. Immunoglobulin abnormalities in the Guillain-Barre syndrome
35. Relationship between measles virus-specific antibody activities and oligoclonal IgG in the central nervous system of patients with subacute sclerosing panencephalitis and multiple sclerosis
36. Multiple sclerosis: Relationship to a retrovirus?
37. Multiple sclerosis and human T-cell lymphotrophic retroviruses
38. Amplification and molecular cloning of HTLV- I sequences from DNA of multiple sclerosis patients
39. HTLU-1 and tropical spastic paraparesis [Letter]
40. The G and Brahic M analysis of human T lymphotrophic virus sequences in multiple sclerosis tissue
41. Serologic studies of MS patients, controls, and patients with other neurologic diseases: antibodies to HTLV-I, II, III
42. Human T lymphotrophic virus type I may not be associated with multiple sclerosis in Japan
43. Detection of human T-cell lymphoma virus type I DNA and antigen in spinal fluid and blood of patients with chronic progressive myelopathy
44. Detection of coronavirus RNA and antigen in multiple sclerosis brain
45. Bacterial toxin superantigens activate human T lymphocytes reactive with myelin autoantigens
46. V-Beta specific stimulation of human T cells by staphylococcal toxins
47. The T lymphocyte in experimental allergic encephalomyelitis
48. Adoptive transfer of myelin basic proteinsensitized T cells produces chronic relapsing demyelination disease in mice
49. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt-1+2- T lymphocytes
50. Pathogenesis of Theiler's murine encephalomyelitis virus
51. Cellular immunity in chronic Theiler's virus central nervous system infection
52. Characterization of Theiler's murine encephalomyelitis virus (TMEV)-specific delayed hypersensitivity response in TMEV-induced demyelinating disease, correlation with clinical signs
53. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1
54. Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis
55. Limited heterogeneity of T-cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention
56. Prevention and treatment of experimental allergic encephalomyelitis by T cell receptor V-beta-specific antibodies
57. Immunization with a synthetic T-Cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis
58. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with MHC proteins
59. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha, beta, integrin
60. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice
61. Isolated pupil-sparing third nerve palsy as the presenting sign of multiple sclerosis
62. The ocular manifestations of multiple sclerosis. Part 2. Abnormalities of eye movements
63. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles
64. Clinical aspects
65. Nystagmus in multiple sclerosis
66. Acquired pendular nystagmus in multiple sclerosis: clinical observations and the role of optic neuropathy
67. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report
68. Formulas for the quantitation of intrathecal IgG production: their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis
69. New diagnostic criteria for multiple sclerosis: guidelines for research protocols
70. Trimodal evoked potentials compared with magnetic resonance imaging in the diagnosis of multiple sclerosis
71. Contribution of MRI to the diagnosis of multiple sclerosis
72. Use of magnetic resonance imaging in the diagnosis of multiple sclerosis: policy statement
73. The role of NMR imaging in the assessment of MS and isolated neurological lesions
74. Magnetic resonance signal abnormalities in asymptomatic individuals: their incidence and functional correlates
75. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis
76. Nuclear magnetic resonance image white matter lesions and risk factors for stroke in normal individuals
77. MRI brain scanning in patients with vasculitis: differentiation from multiple sclerosis
78. Magnetic resonance imaging in central nervous system sarcoidosis
79. MRI findings in neuro-Behcet's disease
80. Assessment of MRI criteria for a diagnosis of MS
81. Patterns of disease activity in multiple sclerosis: a clinical and magnetic resonance imaging study
82. Spinal cord MRI using multi-array coils and fast spin-echo. Part 2. Findings in multiple sclerosis
83. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis
84. Influenzal encephalopathy and post-influenzal encephalitis
85. Lyme disease: recommendations for diagnosis and treatment
86. Human T-lymphocyte virus type I antibodies in the serum of patients with tropical spastic paraparesis in the Seychelles
87. criteria for diagnosis of Behcet's disease
88. The diagnosis of childhood neuro degenerative disorders presenting as dementia in adults
89. Heredodegenerative diseases
90. Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study
91. Transverse myelitis: retrospective analysis of 33 cases, with differentiation of cases associated with multiple sclerosis and parainfectious events
92. Long-term follow-up of acute partial transverse myelopathy
93. Early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord
94. Prognostic significance of brain MRI at presentation with a clinically isolated syndrome suggestive of MS: a five-year follow-up study
95. Devic's neuromyelitis optica and Schilder's myelinoclastic diffuse sclerosis
96. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
97. Multiple sclerosis: early prognostic guidelines
98. Studies on the natural history of multiple sclerosis: eight early prognostic features of the later course of the illness
99. Cardiovascular testing and exercise prescription in multiple sclerosis patients
100. Multiple sclerosis. Part 1. Common physical disabilities and rehabilitation
101. Multiple sclerosis and gestation
102. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients
103. Pregnancy and multiple sclerosis: a prospective study
104. Pregnancy and multiple sclerosis
105. The effect of pregnancy in multiple sclerosis
106. The effects of induced hyperthermia on patients with multiple sclerosis
107. Clinical viral infections and multiple sclerosis
108. Multiple sclerosis: treatment of acute exacerbations with corticotropin (ACTH)
109. Use of oral corticosteroids in the treatment of multiple sclerosis: a double-blind study
110. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: Part 1. Clinical effects
111. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
112. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis
113. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis
114. Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1
115. Clinical experience with COP-1 in multiple sclerosis
116. Clinical experience with azathioprine: the pros
117. Azathioprine in multiple sclerosis: the cons
118. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial
119. Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of highdose intravenous cyclophosphamide, plasma exchange, and ACTH
120. Experience with cyclophosphamide in multiple sclerosis: the cons
121. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group
122. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis
123. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study
124. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis
125. Cladribine in treatment of chronic progressive multiple sclerosis
126. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis
127. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
128. Amantadine therapy for fatigue in multiple sclerosis
129. Depression and multiple sclerosis
130. A double-blind, randomized crossover trial of pemoline in fatigue associated with multiple sclerosis
131. New advances in symptom management in multiple sclerosis
132. Antispasticity drugs: mechanisms of action
133. Intrathecal baclofen for spasticity of spinal origin: seven years of experience
134. Safety and efficacy of tizanidine in therapy of spasticity secondary to multiple sclerosis
135. Management of bladder dysfunction in multiple sclerosis
136. Urological and sexual problems in multiple sclerosis
137. The role of yohimbine for the treatment of erectile impotence
138. Treatment of pathologic laughing and weeping with amitriptyline
139. Suicide in the medical patient
140. A controlled trial of isoniazid therapy for action tremor in multiple sclerosis
141. Pain syndromes in multiple sclerosis
142. Cognitive dysfunction in multiple sclerosis. Part 1. Frequency, patterns, and prediction
143. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: a mechanism for autoimmunity
144. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein
145. FDG-PET, MRI and NMR spectroscopy of normal appearing white matter (NAWM) in multiple sclerosis